No, the shingles vaccine has not been proven to prevent dementia. Research has found lower rates of dementia diagnoses among some vaccinated groups, but these findings come mainly from observational and quasi-experimental studies. Shingrix is approved and recommended to prevent shingles, not dementia. For example, a large Welsh study reported fewer dementia diagnoses after shingles vaccination, but it examined the older Zostavax vaccine rather than the Shingrix vaccine used in the United States today.
The distinction matters because an association can arise for several reasons. A vaccine might directly or indirectly reduce dementia risk, but vaccinated people may also differ from unvaccinated people in preventive care, smoking, income, physical health, or access to medical services. Researchers use matching and statistical adjustments to reduce those differences, yet they cannot always remove them completely. As of July 25, 2026, the evidence is promising enough to justify further research but not a claim that Shingrix prevents dementia. A randomized trial specifically investigating Shingrix for dementia prevention is recruiting, but it has not produced results.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Does the Shingles Vaccine Prevent Dementia, or Is This Only an Association?
- What the Strongest Natural Experiment Actually Found
- What Shingrix Studies Say About Dementia Diagnoses
- How to Make a Practical Shingles Vaccination Decision
- Why Association Is Not Proof of Dementia Prevention
- How Researchers Could Establish Cause and Effect
- Shingrix, Zostavax, and the Risk of Mixing Up the Evidence
- Frequently Asked Questions
Does the Shingles Vaccine Prevent Dementia, or Is This Only an Association?
Shingrix has a clearly established purpose: preventing shingles and its complications. The FDA approved the recombinant, adjuvanted vaccine on October 20, 2017, initially for shingles prevention in adults 50 and older. Its FDA indication now includes adults 50 and older and adults 18 and older who are or will be immunodeficient or immunosuppressed because of disease or treatment. dementia prevention is not an approved indication. CDC recommendations similarly focus on shingles.
The agency recommends two Shingrix doses for adults 50 and older and for adults 19 and older with weakened immune systems due to disease or therapy. In immunocompetent adults 50 and older, CDC reports that shingles vaccination is more than 90% effective against shingles and postherpetic neuralgia, the persistent nerve pain that can continue after the rash disappears. That creates an important comparison. The vaccine’s protection against shingles is supported by evidence designed to test that outcome and is reflected in regulatory approval and public-health recommendations. The proposed protection against dementia rests on studies in which dementia was identified later in medical records or through quasi-experimental comparisons. Those studies can generate a compelling hypothesis without establishing a dementia-prevention indication.
What the Strongest Natural Experiment Actually Found
A study published in Nature in April 2025 examined 282,541 adults in Wales. eligibility for shingles vaccination was governed by a sharp birth-date cutoff, allowing researchers to compare people born just before the cutoff with people born just after it. Because people on either side were close in age, the design reduced some of the “healthy vaccinee” bias found in ordinary comparisons of people who choose vaccination with those who do not. The researchers estimated that receiving the vaccine reduced new dementia diagnoses over seven years by 3.5 percentage points, with a 95% confidence interval of 0.6 to 7.1 percentage points. That corresponded to an estimated 20.0% relative reduction, with a 95% confidence interval of 6.5% to 33.4%.
A 3.5-percentage-point absolute change and a 20% relative change describe the same result from different perspectives; they should not be mistakenly added together or treated as interchangeable measures. This was stronger evidence than a routine medical-record association, but it was not an individually randomized clinical trial. The findings applied mainly to people around ages 79 and 80, so they may not translate directly to someone vaccinated at 50 or 60. Most importantly, the study examined the live-attenuated Zostavax vaccine. Shingrix became available in the United Kingdom only after the study’s follow-up had ended, and Zostavax has not been available in the United States since November 18, 2020.
What Shingrix Studies Say About Dementia Diagnoses
A 2024 Nature Medicine study compared electronic-health-record cohorts from different shingles-vaccine eras. After matching, each cohort included 103,837 people. The newer cohort consisted mostly of recombinant-vaccine recipients, while the comparison involved the prior live vaccine. Over six years, the recombinant-vaccine group had a restricted-mean-time-lost ratio of 0.83, which the researchers described as 17% more time without a dementia diagnosis. Among people affected, that amounted to 164 additional diagnosis-free days. This result is relevant to Shingrix, but the comparison was not the same as randomly assigning similar participants to Shingrix or a placebo.
Changes between vaccine eras could include differences in clinical practice, diagnostic patterns, population health, vaccine uptake, and available medical records. Matching can balance measured characteristics, but it cannot guarantee balance in factors that were missing, inaccurately recorded, or unknown. A 2026 Kaiser Permanente Southern California study supplied another specific example. Among adults 65 and older, two-dose Shingrix recipients had an adjusted dementia hazard ratio of 0.49 compared with matched unvaccinated people. When the researchers used recipients of the Tdap vaccine as a vaccinated comparison group, the hazard ratio was 0.73. The weaker association against another vaccinated group illustrates why the choice of comparator matters.
How to Make a Practical Shingles Vaccination Decision
An eligible adult should consider Shingrix for its demonstrated benefit against shingles rather than treating possible dementia protection as a reason to expect a guaranteed cognitive outcome. Someone caring for a 72-year-old parent, for example, can discuss vaccination as a way to reduce the chance of shingles and postherpetic neuralgia. Any effect on dementia risk would remain an unconfirmed potential benefit. Shingrix is a recombinant, adjuvanted vaccine, not a live-virus vaccine. The standard series consists of two 0.5-milliliter intramuscular doses, ordinarily administered two to six months apart.
An immunocompromised person who would benefit from completing the series sooner may receive the second dose one to two months after the first. Timing should be discussed with a clinician when immune-suppressing treatment, an acute illness, or another medical consideration affects the schedule. There is also a practical tradeoff between acting on established evidence and waiting for answers to a separate research question. Delaying an indicated shingles vaccine while waiting for dementia-trial results leaves a person without its proven protection against shingles. Receiving Shingrix now does not mean a person should count it as part of a proven dementia-prevention plan.
Why Association Is Not Proof of Dementia Prevention
Healthy-vaccinee bias is one of the central problems. People who complete a two-dose vaccine series may be more likely to attend preventive appointments, manage blood pressure, exercise, avoid smoking, or seek earlier treatment for other conditions. They may also differ in education, income, frailty, insurance coverage, and family support. Some of these variables are measurable; others are not captured well in health records. The Kaiser Permanente study makes this issue concrete. Before statistical weighting, vaccinated participants differed from unvaccinated participants in preventive-care use, smoking, body mass index, and income-related measures.
Its comparison with Tdap recipients was therefore especially informative: both groups had demonstrated a willingness and ability to obtain vaccination. The dementia association remained but was smaller, shifting from a hazard ratio of 0.49 against unvaccinated matches to 0.73 against Tdap recipients. A further warning concerns diagnostic records. A lower rate of documented dementia is not necessarily identical to a lower rate of underlying brain disease. Diagnosis may depend on access to specialists, family recognition of symptoms, frequency of medical visits, cognitive screening, and the clinician’s coding practices. Observational studies can adjust for known differences, but residual confounding and differences in diagnosis remain possible.
How Researchers Could Establish Cause and Effect
A randomized controlled trial can distribute both known and unknown risk factors more evenly by assigning participants to study groups rather than observing who independently obtains vaccination. Researchers would then track prespecified cognitive or dementia outcomes under a defined protocol. A definitive Shingrix dementia-prevention trial is recruiting as of July 25, 2026, but there are no results yet.
Even a randomized trial requires careful interpretation. For example, investigators must decide how long to follow participants, which dementia definitions to use, how to handle deaths and missed assessments, and whether any effect differs by age, sex, immune status, prior shingles, or dementia subtype. Until trial evidence is available, statements that Shingrix “prevents dementia” go beyond what the research has established.
Shingrix, Zostavax, and the Risk of Mixing Up the Evidence
Shingrix and Zostavax should not be treated as interchangeable in dementia discussions. Zostavax was a live-attenuated vaccine and was the product evaluated in the Welsh natural experiment. Shingrix is a recombinant, adjuvanted vaccine given as a two-dose series.
Differences in vaccine technology, immune response, effectiveness, eligibility, and dosing mean that a result for one product cannot automatically be assigned to the other. A headline may cite the Welsh estimate of a 20% relative reduction and then illustrate the story with a Shingrix syringe or recommend today’s vaccine. That presentation hides a crucial limitation: Shingrix was not available in the United Kingdom during the study’s follow-up period. In the United States, the older Zostavax product has been unavailable since November 18, 2020.
Frequently Asked Questions
Is Shingrix approved to prevent dementia?
No. The FDA indication for Shingrix is prevention of herpes zoster, commonly called shingles. It covers adults 50 and older and adults 18 and older who are or will be immunodeficient or immunosuppressed because of disease or therapy.
Did the 2025 Welsh study evaluate Shingrix?
No. It evaluated Zostavax, the older live-attenuated shingles vaccine. Shingrix became available in the United Kingdom only after the study’s follow-up ended.
Does a 20% relative reduction mean 20 fewer dementia cases among every 100 vaccinated people?
No. The Welsh study estimated a 20.0% relative reduction and a 3.5-percentage-point absolute reduction over seven years. Relative and absolute changes use different reference points, so the relative figure should not be interpreted as 20 fewer cases per 100 people.
Why compare Shingrix recipients with Tdap recipients?
Vaccinated comparison groups can be more similar in healthcare-seeking behavior than unvaccinated groups. In the Kaiser Permanente study, the adjusted dementia hazard ratio was 0.49 against unvaccinated matches but 0.73 against Tdap recipients, showing how comparator choice can affect the estimated association.
Should someone get Shingrix solely to prevent dementia?
Current evidence does not support promising dementia prevention. Eligible people can consider Shingrix for its established protection against shingles and postherpetic neuralgia while treating a possible cognitive benefit as unproven.
